MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a study finds.
Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback